Results 11 to 20 of about 22,003 (134)

Regulation and Mechanism of Deleted in Breast Cancer-1 on Dendritic Cell Function in Systemic Lupus Erythematosus. [PDF]

MedComm (2020)
LPS‐stimulated DC activation upregulated DBC1. DBC1‐deficient DC ameliorated murine SLE symptoms. DBC1 deficiency suppressed immune responses in DC. DBC1 deficiency lowered STAT5 expression and subsequent phosphorylation. STAT5 overexpression abolished murine SLE remission primed by DBC1 deficiency.
Xiao ZX, Liang R, Liu Y, Huang C, Fang Q, Hu X, Wang J, Olsen N, Wu D, Zheng SG.   +9 more
europepmc   +2 more sources

Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence [PDF]

Laboratory Investigation, 2016
B7-H1 binding to programmed death-1 may deliver a coinhibitory signal to T cells that is involved in the regulation of T-cell activation and tolerance. B7-H1 plays a key role in dysfunction of dendritic cells (DCs) during chronic HBV infection, but the expression mechanism of B7-H1 remains unclear.
Man, Li, Zhen-Hua, Zhou, Xue-Hua, Sun, Xin, Zhang, Xiao-Jun, Zhu, Shu-Gen, Jin, Ya-Ting, Gao, Yun, Jiang, Yue-Qiu, Gao   +8 more
openaire   +2 more sources

Identification of c-Met on Tumor Cells as a Novel Receptor for B7-H3 Entails Implications for Cancer Cell Stemness and Targeted Therapy. [PDF]

MedComm (2020)
B7‐H3 and c‐Met interaction is revealed to be crucial in maintaining cancer cell stemness primarily via c‐Met/STAT3 signaling pathway. B7‐H3 antibody blocking this newly identified interaction exhibits preclinical effects as a new and potent intervention for molecular targeted therapy.
Cao L, Xu Y, Hu Y, Huang X, Fu F, Zhan S, Huang L, Feng Y, Irene Y, Li H, Markku V, Jorma KO, Zhang G, Lu B, Wang J, Liu W, Zhang X.   +16 more
europepmc   +2 more sources

Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma

Journal of Applied Oral Science, 2022
Lower lip squamous cell carcinomas (LLSCC) could be associated with a previous history of potentially malignant oral diseases (PMOD), especially actinic cheilitis (AC), with high sun exposure being a well-described risk factor. Immune evasion mechanisms,
Vinícius Gonçalves de Souza, Damilys Joelly Souza Santos, Ana Gabriela Silva, Rosy Iara Maciel de Azambuja Ribeiro, Adriano Mota Loyola, Sérgio Vitorino Cardoso, Carla Silva Siqueira Miranda, Ludimila Paula Vaz Cardoso   +7 more
doaj   +1 more source

B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models

OncoImmunology, 2020
The application of chimeric antigen receptor (CAR)-T cell therapy in patients with advanced solid tumors remains a significant challenge. Simultaneously targeting antigen and the solid tumor microenvironment are two major factors that greatly impact CAR ...
Baozhu Huang, Liqun Luo, Jun Wang, Bailin He, Rui Feng, Na Xian, Qiong Zhang, Lieping Chen, Gangxiong Huang   +8 more
doaj   +1 more source

Development of a Novel Extracellular Vesicle‐Based Biomarker Approach for Pediatric High‐Grade Glioma [PDF]

J Extracell Biol
ABSTRACT Pediatric high‐grade gliomas (pHGGs) account for 20% of childhood brain tumours and are associated with poor survival. Currently, pHGG detection relies on MRI, a costly and time‐consuming procedure. Extracellular vesicles (EVs) carry molecular markers indicative of their cellular origin and can be isolated from various biofluids, offering an ...
Fernandez Garcia A, Iyer P, Ashi P, Tella I, Sangaraboina V, Bhagat D, Janarthanam C, Bargues‐Carot A, Kanthasamy A, Spoerer T, Golan M, Stice S, Funato K.   +12 more
europepmc   +2 more sources

Targeting the PD-1/PD-L1 Axis in Human Vitiligo

Frontiers in Immunology, 2020
Autoreactive CD8+ T cells play a pivotal role in melanocyte destruction in autoimmune vitiligo. Immunotherapy for melanoma often leads to autoimmune side-effects, among which vitiligo-like depigmentation, indicating that targeting immune checkpoints can ...
Marcella Willemsen, Cornelis J. M. Melief, Marcel W. Bekkenk, Rosalie M. Luiten   +3 more
doaj   +1 more source

Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]

, 2015
Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core   +2 more sources

Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells

Haematologica, 2013
Clinical trials of immunotherapy in mantle cell lymphoma have not yet delivered desirable results, partly because of the inhibitory machinery of the tumor and its microenvironment.
Lijuan Wang, Jianfei Qian, Yong Lu, Haiyan Li, Hanying Bao, Donghua He, Zhiqiang Liu, Yuhuan Zheng, Jin He, Yi Li, Sattva Neelapu, Jing Yang, Larry W. Kwak, Qing Yi, Zhen Cai   +14 more
doaj   +1 more source

CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]

, 2018
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro, Arcieri, Stefano, Baldini, Enke, Barollo, Susi, Carbotta, Giovanni, Catania, Antonio, Fallahi, Poupak, Mian, Caterina, Monti, Massimo, Palmieri, Andrea, Pironi, Daniele, Sorrenti, Salvatore, Tartaglia, Francesco, Tuccilli, Chiara, Ulisse, Salvatore, Vergine, Massimo   +15 more
core   +3 more sources